First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

NCT01215136 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped Lack of Accrual

Conditions

Transitional Cell Carcinoma
Bladder Carcinoma
Urothelial Carcinoma

Interventions

DRUG: Everolimus
DRUG: Everolimus
DRUG: Paclitaxel

Sponsor

Matthew Galsky

Collaborators

[object Object]
[object Object]